[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100569186":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":10,"centralContacts":19,"locations":25,"responsibleParty":57,"collaborators":61,"id":63,"slug":64,"hasResults":65,"nctId":66,"briefTitle":67,"officialTitle":67,"acronym":10,"eligibilityCriteria":68,"healthyVolunteers":69,"sex":70,"minAge":71,"maxAge":72,"enrollmentInfo":73,"targetDuration":76,"studyType":77,"phases":10,"briefSummary":78,"conditions":79,"keywords":85,"overallStatus":28,"whyStopped":10,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":97},{"fullName":5,"class":6},"Tianjin Medical University","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Single Group Assignment",null,"Each subject receive a single intravenous injection of 68Ga\u002F18F-PSMA\u002FPSFA, and undergo PET\u002FCT imaging within the specificed time.",[13],"Diagnostic Test: 68Ga\u002F18F-PSMA\u002FPSFA",[15],{"type":16,"name":17,"description":11,"armGroupLabels":18,"otherNames":10},"DIAGNOSTIC_TEST","68Ga\u002F18F-PSMA\u002FPSFA",[9],[20],{"name":21,"role":22,"phone":23,"phoneExt":10,"email":24},"Haonan Yu, MD","CONTACT","+8613821000597","dreamadam@126.com",[26,45],{"facility":27,"status":28,"city":29,"state":30,"zip":31,"country":32,"countryCode":33,"cosmosGeoPoint":34,"geoPoint":39,"contacts":40},"The First Affiliated Hospital of University of Science and Technology of China","RECRUITING","Hefei","Anhui","230000","China","CN",{"type":35,"coordinates":36},"Point",[37,38],117.28083,31.86389,{"lat":38,"lon":37},[41],{"name":42,"role":22,"phone":43,"phoneExt":10,"email":44},"Qiang Xie, PhD","+8613721108043","ahxq1980@163.com",{"facility":46,"status":28,"city":47,"state":48,"zip":49,"country":32,"countryCode":33,"cosmosGeoPoint":50,"geoPoint":54,"contacts":55},"Tianjin Medical University General Hospital","Tianjin","Tianjin Municipality","300052",{"type":35,"coordinates":51},[52,53],117.17667,39.14222,{"lat":53,"lon":52},[56],{"name":21,"role":22,"phone":23,"phoneExt":10,"email":24},{"type":58,"investigatorFullName":59,"investigatorTitle":60,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","Shaobo Yao, PhD","Prof.",[62],{"name":46,"class":6},"100569186","prostate-specific-membrane-antigen-petct-imaging-in-psma-related-disease-patients-100569186",false,"NCT06690970","Prostate Specific Membrane Antigen PET\u002FCT Imaging in PSMA-Related Disease Patients","Inclusion Criteria:\n\n\\- (i) adult patients (aged 18 years or order); (ii) patients with suspected or new diagnosed or previously treated malignant tumors (supporting evidence may include MRI, CT, tumor markers and pathology report); (iii) patients who had scheduled PSMA PET\u002FCT scan; (iv) patients who were able to provide informed consent (signed by participant, parent or legal representative) and assent according to the guidelines of the Clinical Research Ethics Committee.\n\nExclusion Criteria:\n\n\\- (i) patients with non-malignant lesions; (ii) patients with pregnancy; (iii) the inability or unwillingness of the research participant, parent or legal representative to provide written informed consent.",true,"ALL","18 Years","80 Years",{"count":74,"type":75},500,"ESTIMATED","7 Days","OBSERVATIONAL","To evaluate the potential usefulness of 68Ga\u002F18F-PSMA\u002FPSFA positron emission tomography\u002Fcomputed tomography (PET\u002FCT) for the diagnosis of primary and metastatic lesions in various PSMA-related disease patients.",[80,81,82,83,84],"PSMA-related Disease","Prostate Cancer","Positron Emission Tomography","Metastasis","FAP",[86,87,84],"PET\u002FCT","PSMA","2025-08-07",{"date":90,"type":91},"2025-08-11","ACTUAL",{"date":93,"type":91},"2020-09-01",{"date":95,"type":75},"2027-12-01",{"name":5,"class":6},2]